RXi Pharmas Gene Therapy Gets Patent Boost
News Apr 20, 2016
This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.
"We are pleased to have be granted this Notice of Allowance from the USPTO," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis".
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018